Noninvasive biomarker tests diagnose urothelial cancer in patients with hematuria

“What was very impressive from the study was by sequentially using Cxbladder Triage, Detect, and Resolve, we could not only segregate those who had cancer versus not, but also those who had low-risk tumors versus high-risk tumors,” says Jay Raman, MD, FACS.

In this video, Jay Raman, MD, FACS,discusses the findings and takeaways of the study, “The diagnostic performance of Cxbladder Resolve, alone and in combination with other Cxbladder tests, in the identification and priority evaluation of patients at risk for urothelial carcinoma,” published in the Journal of Urology. Raman is a professor and chair of urology at Penn State Health Milton S. Hershey Medical Center, Penn State University, Pennsylvania.

Related Videos
Doctor receiving patient in office | Image Credit © Africa Studio -
Alisa J. Stephens-Shields, PhD, answers a question during a Zoom video interview
Blurred interior of hospital | Image Credit: © jakkapan -
Dr. David Sheyn in an interview with Urology Times
Avinash Maganty, MD, answers a question during a Zoom video interview
blur image background of corridor in hospital or clinic image | Image Credit:  © whyframeshot -
Rachel Pope, MD, MPH, answers a question during a Zoom interview
Dr. David Canes in an interview with Urology Times
Urinary bladder | Image credit: © magicmine -
Related Content
© 2023 MJH Life Sciences

All rights reserved.